<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Cetuximab was demonstrated by clinical trials to improve response rate and survival of patients with metastatic and nonresectable <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> or <z:mp ids='MP_0002038'>carcinoma</z:mp> of the head and neck </plain></SENT>
<SENT sid="1" pm="."><plain>Appropriate management of <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> associated with epidermal growth factor receptor inhibitor (EGFR-i) therapy is necessary to allow adequate drug administration and to improve quality of life and outcomes </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: A group of Italian Experts produced recommendations for <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> management using the RAND/UCLA Appropriateness Method </plain></SENT>
<SENT sid="3" pm="."><plain>Statements were generated on the basis of a systematic revision of the literature and voted twice by a panel of 40 expert physicians; the second vote was preceded by a meeting of the panelists </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">Skin toxicity</z:e> included <z:hpo ids='HP_0000988'>skin rash</z:hpo>, skin dryness, <z:hpo ids='HP_0000989'>pruritus</z:hpo>, <z:hpo ids='HP_0001818'>paronychia</z:hpo>, <z:hpo ids='HP_0001595'>hair abnormality</z:hpo>, and mucositis </plain></SENT>
<SENT sid="5" pm="."><plain>Recommendations for prophylaxis and therapeutic interventions for each type of toxicity were proposed </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Interventions that were considered appropriate to improve compliance and outcomes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients treated with EGFR-i were identified </plain></SENT>
</text></document>